
Phosphatidylserine
CAS No. 51446-62-9
Phosphatidylserine ( Distearoyl phosphatidylserine | Phosphatidylserine(36:0) | Dioctadecanoylphosphatidylserine | C42H82NO10P )
产品货号. M24482 CAS No. 51446-62-9
磷脂酰丝氨酸是重要的磷脂膜成分,在细胞周期信号传导中发挥关键作用,特别是与细胞凋亡相关。磷脂酰丝氨酸被广泛用作营养补充剂。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
25MG | ¥300 | 有现货 |
![]() ![]() |
50MG | ¥429 | 有现货 |
![]() ![]() |
100MG | ¥624 | 有现货 |
![]() ![]() |
500MG | ¥1766 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Phosphatidylserine
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述磷脂酰丝氨酸是重要的磷脂膜成分,在细胞周期信号传导中发挥关键作用,特别是与细胞凋亡相关。磷脂酰丝氨酸被广泛用作营养补充剂。
-
产品描述Phosphatidylserine is an important phospholipid membrane component, plays a key role in cell cycle signaling, specifically in relationship to apoptosis. Phosphatidylserine is widely used as a nutritional supplement.
-
体外实验——
-
体内实验——
-
同义词Distearoyl phosphatidylserine | Phosphatidylserine(36:0) | Dioctadecanoylphosphatidylserine | C42H82NO10P
-
通路Others
-
靶点Other Targets
-
受体Others
-
研究领域——
-
适应症——
化学信息
-
CAS Number51446-62-9
-
分子量792.07
-
分子式C42H82NO10P
-
纯度>98% (HPLC)
-
溶解度DMSO:Soluble; Water:Insoluble
-
SMILESCCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCC(C(=O)O)N)OC(=O)CCCCCCCCCCCCCCCCC
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献




-
16alpha-Hydroxypredn...
16α-羟基泼尼松龙是糖皮质激素布地奈德 22(R) 差向异构体的立体选择性代谢物。
-
C-Reactive Protein (...
C-Reactive Protein (CRP) 77-82 is the 77-82 fragment of C-Reactive Protein. C-Reactive Protein (CRP), the prototypic marker of inflammation, is a cardiovascular risk marker and may promote atherogenesis.C-reactive protein (CRP) is an annular (ring-shaped), pentameric protein found in blood plasma, whose circulating concentrations rise in response to inflammation. It is an acute-phase protein of hepatic origin that increases following interleukin-6 secretion by macrophages and T cells.
-
MAGE-A3 195-203
This peptide MAGE-3-encoded HLA-A24 epitope is a high MHC binder.The identification of this MAGE-3/HLA-A24 peptide may as a result effectiveially offer the opportunities to design peptide-based immunotherapeutic approaches that might prove to be potent in treating patients with MAGE-3-positive malignant tumors.